Home/Investors/Foresite Capital

Foresite Capital

Biotech Investor · 3 portfolio companies

Portfolio

3

Combined Value

$7.0B

Focus Areas

4

Top Stage

Phase 2

Investment Focus

Metabolic Diseases Cardiovascular Pulmonary Oncology

Portfolio Companies

Company	Stage	Valuation	Focus
Structure Therapeutics	Phase 2	$3.4B	Metabolic Diseases, Cardiovascular
Tango Therapeutics	Phase 1/2	$2.8B	Oncology
CytomX Therapeutics	Phase 1	$757.3M	Oncology

Frequent Co-Investors

Public market investors1 shared Longitude Capital1 shared Arch Venture Partners1 shared BVF Partners1 shared Other institutional investors from IPO1 shared RA Capital Management1 shared Other institutional investors1 shared Third Rock Ventures1 shared